The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.
Net Trade Sales of CARVYKTI: Approximately $286 million, an 87.6% increase year-over-year and a 53.2% increase ...
The increasing uptake of Carvykti, driven by its attractive clinical profile and favorable outpatient dosing, has led to significant sales growth. The company’s efforts to expand manufacturing ...
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...
Turning to our highlights. In the third quarter, we are pleased that CARVYKTI cells continued their strong momentum, ...
In a recent earnings call, Legend Biotech (NASDAQ: LEGN) reported a significant increase in net sales for its CARVYKTI treatment, with a notable 87.6% year-over-year growth, reaching approximately ...
In a recent earnings call, Legend Biotech (NASDAQ: LEGN) reported a significant increase in net sales for its CARVYKTI treatment, with a notable 87.6% year-over-year growth, reaching approximately ...
The Legend Biotech management team robustly defended the efficacy and safety profile of their product Carvykti, amidst market reactions to the competitor's data. The analyst noted that the ...
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback